DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07321678

Active not recruitingPhase 2

A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

Asset

ASC30

Oral · GLP-1 agonist

Listed sites

8

Recruiting sites

—

Enrollment

100

estimated

Study population

Type 2 diabetes

Key I/E criteria

•BMI ≥23•HbA1c 7-10.5%

Primary endpoint

•HbA1c up

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07321678
Org study IDASC30-203

Timeline

Milestones

Study first posted2026-01-07actual
Study start2026-01-22actual
Last update posted2026-04-30actual
Primary completion2026-08estimated (month precision)
Study completion2026-08estimated (month precision)

Assets

Investigational agents

ASC30

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Have Type 2 Diabetes (T2D)
•Have HbA1c ≥7.0% to ≤10.5% as determined by the central laboratory at screening.
•Stable body weight (less than 5% self-reported change within the previous 3 months).
•Have a BMI ≥23.0 kilogram/square meter (kg/m²) at screening.

Exclusion criteria

•Have any prior diagnosis of type 1 diabetes mellitus (T1DM), or rare forms of diabetes mellitus
•Have had more than 1 episode of severe hypoglycemia
•Have poorly controlled hypertension
•Have acute or chronic hepatitis and pancreatitis
•Have evidence of a significant active and uncontrolled medical condition

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
2
Weight & body composition
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Mean change from baseline in body weight up to 13 weeks in the treatment group compared with placebo group

Time frame:Baseline and end of Week 13

change from baseline, improvement

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint

Mean change from baseline in HbA1c up to 13 weeks in the treatment group compared with the placebo group

Time frame:Baseline and end of Week 13

change from baseline, improvement

Secondary/protocol endpoint

Mean change from baseline in fasting blood glucose up to 13 weeks in the treatment group compared with the placebo group

Time frame:Baseline and end of Week 13

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.